These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17353347)

  • 1. Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method.
    Wickremsinhe ER; Tian Y; Ruterbories KJ; Verburg EM; Weerakkody GJ; Kurihara A; Farid NA
    Drug Metab Dispos; 2007 Jun; 35(6):917-21. PubMed ID: 17353347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry.
    Farid NA; McIntosh M; Garofolo F; Wong E; Shwajch A; Kennedy M; Young M; Sarkar P; Kawabata K; Takahashi M; Pang H
    Rapid Commun Mass Spectrom; 2007; 21(2):169-79. PubMed ID: 17154350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The disposition of prasugrel, a novel thienopyridine, in humans.
    Farid NA; Smith RL; Gillespie TA; Rash TJ; Blair PE; Kurihara A; Goldberg MJ
    Drug Metab Dispos; 2007 Jul; 35(7):1096-104. PubMed ID: 17403916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
    Asai F; Jakubowski JA; Naganuma H; Brandt JT; Matsushima N; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):209-17. PubMed ID: 16769598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
    Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
    Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
    Dobesh PP
    Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.
    Williams ET; Jones KO; Ponsler GD; Lowery SM; Perkins EJ; Wrighton SA; Ruterbories KJ; Kazui M; Farid NA
    Drug Metab Dispos; 2008 Jul; 36(7):1227-32. PubMed ID: 18372401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
    Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
    Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intestine as an important contributor to prasugrel active metabolite formation in vivo.
    Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Izumi T; Ikeda T; Kurihara A
    Drug Metab Dispos; 2011 Apr; 39(4):565-70. PubMed ID: 21189331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
    Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Small DS; Farid NA; Payne CD; Weerakkody GJ; Li YG; Brandt JT; Salazar DE; Winters KJ
    J Clin Pharmacol; 2008 Apr; 48(4):475-84. PubMed ID: 18303127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
    Frelinger AL; Jakubowski JA; Li Y; Barnard MR; Linden MD; Tarnow I; Fox ML; Sugidachi A; Winters KJ; Furman MI; Michelson AD
    J Thromb Haemost; 2008 Feb; 6(2):359-65. PubMed ID: 18021304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS.
    Takahashi M; Pang H; Kawabata K; Farid NA; Kurihara A
    J Pharm Biomed Anal; 2008 Dec; 48(4):1219-24. PubMed ID: 18829199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
    Alban S
    Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350
    [No Abstract]   [Full Text] [Related]  

  • 17. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
    Sugidachi A; Ogawa T; Kurihara A; Hagihara K; Jakubowski JA; Hashimoto M; Niitsu Y; Asai F
    J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel.
    Hagihara K; Kazui M; Kurihara A; Kubota K; Ikeda T
    Drug Metab Dispos; 2011 Feb; 39(2):208-14. PubMed ID: 21036950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
    Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Takahashi M; Kurihara A; Okazaki O; Farid NA; Ikeda T
    Xenobiotica; 2009 Mar; 39(3):218-26. PubMed ID: 19280520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.